UnitedHealthcare (UHC), the second-largest U.S. commercial insurance provider, issued a positive medical policy for Lumbar Total Disc Replacement (TDR).
UHC covers over 16 million patients; now three of the four largest U.S. commercial providers have positive coverage for Centinel Spine’s prodisc® L anterior lumbar total disc. A recent policy change by TRICARE, the Military Health System, added 9.5 million covered lives; combined, these decisions give >25 million additional patients access to prodisc L.
Over 400 publications have demonstrated long-term effectiveness in >125,000 prodisc patients during 30+ years of clinical evidence generated by Centinel Spine and its originators.
The Viscogliosi Bros. purchased prodisc-L from Aesculap in 1999 and spun it into a standalone company, Spine Solutions, which commercialized prodisc-C and commenced U.S. clinical trials. Synthes purchased Spine Solutions in 2Q03. In 2017, Centinel Spine acquired worldwide prodisc TDR assets from DePuy Synthes Products.
Sources: Centinel Spine, LLC; ORTHOWORLD Inc.
Image courtesy of Centinel Spine, LLC
UnitedHealthcare (UHC), the second-largest U.S. commercial insurance provider, issued a positive medical policy for Lumbar Total Disc Replacement (TDR).
UHC covers over 16 million patients; now three of the four largest U.S. commercial providers have positive coverage for Centinel Spine's prodisc® L anterior lumbar total disc. A recent...
UnitedHealthcare (UHC), the second-largest U.S. commercial insurance provider, issued a positive medical policy for Lumbar Total Disc Replacement (TDR).
UHC covers over 16 million patients; now three of the four largest U.S. commercial providers have positive coverage for Centinel Spine’s prodisc® L anterior lumbar total disc. A recent policy change by TRICARE, the Military Health System, added 9.5 million covered lives; combined, these decisions give >25 million additional patients access to prodisc L.
Over 400 publications have demonstrated long-term effectiveness in >125,000 prodisc patients during 30+ years of clinical evidence generated by Centinel Spine and its originators.
The Viscogliosi Bros. purchased prodisc-L from Aesculap in 1999 and spun it into a standalone company, Spine Solutions, which commercialized prodisc-C and commenced U.S. clinical trials. Synthes purchased Spine Solutions in 2Q03. In 2017, Centinel Spine acquired worldwide prodisc TDR assets from DePuy Synthes Products.
Sources: Centinel Spine, LLC; ORTHOWORLD Inc.
Image courtesy of Centinel Spine, LLC
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.